Paper Details

  1. Home
  2. Paper Details

A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.

Author: ChenPo-Huang, HoChing-Liang, LeeCho-Hao, LinChin, WangChieh-Yung

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Chronic lymphocytic leukemia (CLL) is a type of cancer that can't be cured with standard treatments. While initial treatments are often effective, most people eventually experience a return of the cancer within five years. Maintaining treatment with medications like lenalidomide, rituximab, or ofatumumab may help to keep the disease in remission for a longer period compared to not using these medications. However, more research is needed to compare the effectiveness and safety of these different maintenance therapies.
Paper Details　
Original Abstract of the Article :
Chronic lymphocytic leukemia (CLL) is incurable through conventional chemoimmunotherapy regimens. Despite durable responses to front-line therapy and sustained remission rates in patients with CLL, a majority of patients eventually relapse in 5 years of initial treatment. The depth of the response m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988939/

データ提供：米国国立医学図書館（NLM）

Maintenance Therapy for Chronic Lymphocytic Leukemia: A Network Meta-Analysis

Chronic lymphocytic leukemia (CLL) is a challenging disease that requires ongoing management. This study examines the effectiveness of different maintenance therapies for patients with CLL. The researchers performed a network meta-analysis to compare the effects of various treatments, including lenalidomide, rituximab, and ofatumumab, on disease control and safety.

Maintenance Therapy: Prolonging Remission and Managing CLL

The analysis showed that lenalidomide, rituximab, and ofatumumab demonstrated some efficacy as maintenance therapies compared to no intervention. However, the relative effects of different maintenance therapies on disease control and safety remained unclear. It's like having a caravan of camels, each with its own strengths and weaknesses, and needing to choose the right one for the journey.

Navigating the Desert of CLL: A Need for More Research

The study calls for further research to clarify the relative effectiveness and safety of different maintenance therapies for CLL. This information will help healthcare providers make informed decisions about the best treatment options for their patients. As we continue to explore the desert of CLL treatment, finding the most effective and safe therapies is a continuous quest.

Dr. Camel's Conclusion

This study highlights the importance of exploring different maintenance therapies for CLL to maximize the benefits and minimize the risks for patients. While we've made progress in understanding CLL treatment, the journey continues. As we venture deeper into the desert of this disease, we seek new knowledge and innovative therapies that can bring hope and healing to those affected.

Date :
  1. Date Completed 2020-04-06
  2. Date Revised 2020-04-08
Further Info :

Pubmed ID

31995577

DOI: Digital Object Identifier

PMC6988939

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.